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HIGHLIGHTS 
1. First report of an enzyme-linked immunosorbent assay (ELISA) to detect fragments 
of the protein CDCP1 in human serum 
2. The ELISA has a wide working range of 0.68 to 26.5 ng/ml, and a low limit of 
detection of 
0.25 ng/ml 
3. The ELISA has high intra-assay (repeatability) and high inter-assay (reproducibility) 
precision with all coefficients of variation ≤ 7% 
4. The ELISA displays high accuracy detecting ShE-CDCP1 levels at ≥ 94.8% of actual 
concentration 
5. Because CDCP1 has potential as a biomarker for colorectal, prostate, breast, kidney 
and ovarian cancer, the findings will be relevant to investigators interested in clinical 
applications as well as those interested in the functions of CDCP1. 
 
 
ABSTRACT 
 
CUB domain containing protein 1 (CDCP1) is a transmembrane protein involved in progression 
of several cancers. When located on the plasma membrane, full-length 135 kDa CDCP1 can 
undergo proteolysis mediated by serine proteases that cleave after two adjacent amino acids 
(arginine 368 and lysine 369). This releases from the cell surface two 65 kDa fragments, 
collectively termed ShE-CDCP1, that differ by one carboxyl terminal residue. To evaluate the 
function of CDCP1 and its potential utility as a cancer biomarker, in this study we developed an 
enzyme-linked immunosorbent assay (ELISA) to reliably and easily measure the concentration 
of ShE-CDCP1 in biological samples. Using a reference standard we demonstrate that the 
developed ELISA has a working range of 0.68 to 26.5 ng/ml, and the limit of detection is 0.25 
ng/ml. It displays high intra-assay (repeatability) and high inter-assay (reproducibility) precision 
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with all coefficients of variation ≤ 7%. The ELISA also displays high accuracy detecting ShE-
CDCP1 levels at ≥ 94.8% of actual concentration using quality control samples. We employed 
the ELISA to measure the concentration of ShE-CDCP1 in human serum samples with our 
results suggesting that levels are significantly higher in serum of colorectal cancer patients 
compared with serum from individuals with benign conditions (p < 0.05). Our data also suggest 
that colorectal cancer patients with stage II-IV disease have at least 50% higher serum levels of 
ShE-CDCP1 compared with stage I cases (p < 0.05). We conclude that the developed ELISA is a 
suitable method to quantify ShE-CDCP1 concentration in human serum. 
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1. Introduction 
 
CUB domain containing protein 1 (CDCP1) is a 135 kDa transmembrane protein that contains a 
29 residue amino-terminal signal peptide, a 636 residue glycosylated extracellular domain 
(ECD), and a 150 amino acid cytoplasmic carboxyl-terminal region [1]. It is expressed by 
epithelial cells of most organs [1-3] and its over-expression is associated with poor survival of 
patients with renal cell carcinoma [4, 5], colorectal [6], lung [7, 8], pancreatic [9], and breast 
cancer [10], and clear cell ovarian carcinoma [11]. CDCP1 modulates adhesion and promotes 
motility of cells in vitro [2, 9, 12-14], mediates metastasis in in vivo models [11, 12, 14-17], and 
also contributes to in vitro and in vivo resistance of cancer to chemotherapy [11, 17] and targeted 
agents [10, 18, 19].  
 
A key feature impacting on the biology of CDCP1 is its cleavage by serine proteases. This 
occurs at two adjacent sites, arginine 368 (R368) and lysine 369 (K369), and generates two 65 
kDa amino-terminal fragments that are shed from the cell surface. These are designated ShE-
CDCP1368 and ShE-CDCP1369 (collectively termed ShE-CDCP1) and differ by a single carboxyl-
terminal amino acid [20]. Western blot analysis has revealed elevated levels of ShE-CDCP1 in 
the urine of prostate cancer patients at high risk of poor survival [21], and in conditioned media 
of prostate cancer cell lines [20]. Also, there is indirect evidence from Western blot analyses of 
tissue lysates, that CDCP1 cleavage occurs in high grade serous ovarian carcinoma patients [22], 
and in many cell lines derived from epithelial tumors [3, 20].  Although the functional 
importance of ShE-CDCP1 in cancer has not been directly addressed, recent studies indicate that 
CDCP1 cleavage is necessary for triple negative breast cancer migration [23] and for vascular 
metastasis in animal models [15, 16].  
 
To facilitate the evaluation of ShE-CDCP1 as a disease biomarker and examine its functional 
importance, in this study we developed an enzyme-linked immunosorbent assay (ELISA) to 
determine its concentration in biological specimens. We evaluated the ELISA using serum 
samples from colorectal cancer patients.    
 
2. Materials and Methods 
 
2.1 Antibodies and reagents 
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Mouse monoclonal antibody 10D7 was generated and purified from hybridoma conditioned 
media as previously described [17]. Goat polyclonal anti-CDCP1 antibody AF2666 and 
biotinylated AF2666 were purchased from R&D Systems (In vitro Technologies, Eight Mile 
Plains, Australia). Horseradish peroxidase substrate 3,3',5,5'-tetramethylbenzidine (TMB; 
catalogue number T0440), bovine serum albumin (BSA; catalogue number A3059), Expand high 
fidelity polymerase, polystyrene 96 well Nunc Maxisorp plates and Tween 20 were from Sigma-
Aldrich (Castle Hill, Australia). Vector pcDNA3.1/V5-His, Lipofectamine 2000 transfection 
reagent, G418, Dulbecco's Modified Eagle's Medium (DMEM), immobilized metal affinity 
chromatography (IMAC) nickel columns and Slide-A-Lyser cassettes were from Thermo 
Scientific (Mount Waverley, Australia). Buffers used in experiments were: coating buffer 
(carbonate-bicarbonate buffer, pH 9.6), washing buffer (phosphate buffered saline (PBS) with 
0.05% Tween 20 (PBS-T)) and dilution buffer (1% BSA in washing buffer). 
 
2.2 Generation and purification of recombinant CDCP1-ECD  
 
An expression construct encoding amino acids 1 to 665 of CDCP1 (incorporating the signal 
peptide and ECD) was generated from a previously described expression construct [20]. Expand 
high fidelity polymerase was used to amplify the sequence by PCR and the product, 
incorporating 5ʹ EcoRI and 3ʹ NotI restriction sites, was ligated into the vector pcDNA3.1/V5-
His in-frame with DNA encoding a carboxyl terminal tag incorporating a V5 epitope and six 
histidine residues. The generated construct was transfected, using Lipofectamine 2000, into 
HEK293 cells grown in DMEM and stably expressing cells were selected in media containing 
G418 (1.2 mg/ml) before expansion of clonal cell populations. Recombinant CDCP1-ECD 
(rCDCP1-ECD) was purified from serum free culture medium conditioned for 48 h. The media 
was centrifuged at 2000 g for 10 minutes, the supernatant was mixed with an equal volume of 
PBS, filtered through a 0.45 μm filter and concentrated in centrifugal filter units with a 50 kDa 
molecular weight cut-off at 4000 g. The retentate, containing rCDCP1-ECD, was dialysed twice 
overnight against PBS at 4°C in a Slide-A-Lyser cassette with a 10 kDa molecular weight cut-
off. Partially purified rCDCP1-ECD was further purified by affinity chromatography using a 
nickel column, then the purified material was buffer exchanged into PBS and analyzed on a 
denaturing silver stained gel as previously described [24]. The gel also contained a dilution series 
of known amounts of BSA. The purity and concentration of rCDCP1-ECD was determined from 
the silver stained gel using a Li-COR imaging system and associated Odyssey V3.0 software 
(Millennium Science, Mulgrave, Australia) by interpolating from an equation of best-fit 
generated from the BSA standards. 
 
2.3 Assessment of the specificity of capture antibody 10D7 and detection antibody AF2666 
 
Expression constructs encoding the two ShE-CDCP1 fragments were generated by site directed 
mutagenesis. This introduced a stop codon at either codon 369 or 370 of a previously described 
construct encoding full-length CDCP1 [20]. The two generated constructs were transfected into 
HEK293 cells and stably expressing cells selected in media containing G418 (1.2 mg/ml). 
Immunoprecipitation was performed on 48 h conditioned media from HEK293 cells stably 
expressing ShE-CDCP1368, ShE-CDCP1369 or CDCP1-ECD, using antibody 10D7 or isotype 
matched immunoglobulin (IgG). Immunopecipitated proteins and conditioned media were 
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analysed by Western blot analysis using antibodies 10D7 and AF2666, as previously described 
[20] 
 
2.4 ELISA development and optimization 
 
A sandwich ELISA was developed for detection of ShE-CDCP1. The ELIZA was optimized for 
blocking buffer, dilution buffer, temperature and time period of incubations, and concentration of 
capture and detection antibodies using previously described approaches [25-29]. The following 
briefly summarizes the optimized protocol. Plates (96 well) were coated overnight at 4°C with 
10D7 (4 µg/ml) in carbonate-bicarbonate coating buffer (100 μl/well), washed once with 
washing buffer then blocked with 2% BSA in washing buffer for 1 h at room temperature. After 
washes, the reference standard, rCDCP1-ECD and human serum samples, diluted 1:5 in dilution 
buffer, were applied to duplicate wells (100 μl/well). The reference standard was applied in a 
two-fold dilution of 24.4, 12.2, 6.1, 3.05, 1.525 and 0.7625 ng/ml/well. After incubated for 1.5 h 
at 37°C wells were washed six times with washing buffer before biotinylated AF2666 (0.2 
µg/ml) in dilution buffer (100 μl/well) was added to the wells. After incubation for 2 h at room 
temperature wells were washed three times, then HRP-conjugated streptavidin (diluted 1/4,000 
in dilution buffer) was added. Following incubation for 30 min at room temperature wells were 
washed six times then TMB (100 μl) was added as the substrate. After 20 min, color 
development was stopped with 1 M H2SO4 and optical density (OD) of each well measured at 
450 nm using a PHERAstar FS plate reader (BMG Labtech, Mornington, Australia). Sample 
values were corrected by subtracting the background reading from wells containing only dilution 
buffer. Assays were performed at least 3 times. The concentration of ShE-CDCP1 present in 
samples was determined using Prism 5 software (GraphPad, La Jolla, CA, USA) by interpolation 
from the reference standard curve generated by a 4-parameter logistic fit of background 
corrected OD readings from the dilution series of the reference standard. Aggregated data are 
displayed as mean ± SEM, and were examined using Prism 5 software for statistically significant 
differences between benign and malignant cases, and between cancer stages using a one way 
ANOVA and Welch’s t-test to adjust for unequal sample sizes. 
 
The optimal amount of capture antibody (10D7) and biotinylated detection antibody (AF2666) 
used in the ELISA was determined as described previously [25]. Briefly, as shown in Table 1 in 
a 96 well plate format 10D7 was applied at 1 µg/ml/well to the wells of the first column of each 
plate and, at amounts increasing by 1 µg/ml/well, to the wells of the next 10 columns up to a 
final amount of 11 µg/ml/well for column 11. The reference standard was aliquoted at 10 
ng/ml/well, then biotinylated AF2666 was applied in a 2-fold dilution series to the wells of the 
plate such that 0.8 µg/ml/well was aliquoted into the wells of the top row of each plate, and 
0.0125 µg/ml/well into the wells of row G. The optimal amount of 10D7 and biotinylated 
AF2666 was selected based on the signal to noise ratio, compared with blank wells containing 
only dilution buffer.  
 
2.5 ELISA validation 
 
Method validation of the ShE-CDCP1 ELISA was performed in accordance with guidelines 
issued by regulatory bodies [30, 31] and following published protocols [25, 26].  
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2.5.1 Minimum required dilution – test for linearity of dilution 
 
To determine the minimum required dilution (MRD), we performed a test for linearity as 
previously described [28, 29]. Serum from five colorectal cancer patients was combined and 
spiked with the reference standard to 80 ng/ml. The ELISA was performed on this neat sample 
and on 1:1, 1:3, 1:5, 1:7, 1:15 and 1:23 dilutions (spiked sample:dilution buffer). Linearity of 
dilution was assessed by the dilution corrected value (i.e. measured concentration multiplied by 
dilution factor) and the percentage change in concentration from the previous dilution (current 
dilution corrected value/previous dilution corrected value x 100) [28]. The lowest dilution at 
which the measured concentration is within 80-120%, and preferably 90-110%, of the previous 
concentration represents the MRD.  
 
2.5.2 Working range of the ELISA - limit of detection and limits of quantification 
 
The limit of detection (LOD) of the assay, the lowest concentration that can be differentiated 
from a blank (ie. the S/N ratio is ≥ 3), was determined as described previously [27] by 
performing the ELISA on 10 blank wells containing only dilution buffer. Absorbance values 
from the ELISA were used to determine from the reference standard curve, generated in Section 
2.4, the mean concentration and standard deviation of the blanks. The LOD is calculated as the 
mean plus 3 standard deviations. The lower limit of quantification (LLOQ), the lowest value 
from the reference standard curve that can be used for quantification, was similarly determined 
as described previously [27] as the mean of the measurements from the 10 blank wells plus 10 
standard deviations. The upper limit of quantification (ULOQ), the highest value from the 
reference standard curve that can be used for quantification, was determined as described 
previously [26], as the value derived from the highest absorbance from the reference standard 
curve for which the coefficient of variation (CV) was less than 10%. 
 
2.5.3. Precision and accuracy 
 
Precision and accuracy of the assay were assessed using quality control (QC) samples as 
described previously [25, 31]. These were generated from equal volumes of serum from five 
colorectal cancer patients that contained negligible concentrations of ShE-CDCP1 as determined 
using the established ELISA. The combined sera was diluted 1:5 with dilution buffer, and then 
spiked with the reference standard to represent cases with low, medium and high concentrations 
of analyte. QC samples were stored as single ready-to-use aliquots at -80°C. Intra-assay 
precision, the repeatability of the ELISA, was evaluated from the CVs between the known and 
measured concentrations determined from three assays performed concurrently on duplicate 
wells of low, medium and high concentration QC samples. Inter-assay precision, the 
reproducibility of the ELISA, was assessed in the same way, except the assays were performed 
independently on three different days. Assay accuracy, the percentage of total analyte detected 
by the assay, was determined from six measurements performed on duplicate wells of the three 
QC samples (low, medium and high concentration). For each QC sample the recovery rate of the 
ELISA is the average measured concentration divided by the actual concentration of the sample. 
Based on the European Medicines Agency guidelines, the precision and accuracy assessed by 
CV should not exceed 15% [31]. 
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2.5.4 Test for parallelism between the reference standard curve and the calibrator curve 
 
We tested for parallelism as previously described [26] comparing ELISA values obtained using 
the reference standard diluted in dilution buffer, and the reference standard diluted in serum 
(referred to as the calibrator). The reference standards consisted of 100 ng/ml and a two-fold 
reducing concentration range of 61 to 0.12 ng/ml diluted in dilution buffer. The calibrator curve 
was generated from the same concentration range of the reference standard but diluted in a buffer 
consisting of equal volumes of serum from five colorectal cancer patients that had been diluted 
1:5 in dilution buffer. Curves of best fit for ELISA OD versus analyte concentration, generated 
for the reference standards and calibrators, were overlaid to assess parallelism. Based on the 
European Medicines Agency guidelines the mean concentration at each level should be within 
20% of the nominal concentration [31]. Parallelism was also assessed by overlaying lines of best 
fit for the same data values transformed as the base-10 logarithm. Comparison between lines of 
best fit was performed by Tukey’s HSD test [32] using Prism 5 software. 
 
 
2.5.5 Sample stability 
 
The stability of serum samples was assessed by performing ELISA measurements on QC 
samples which had been subjected to five cycles of freezing and thawing from -80°C, two freeze 
and thaw cycles from -20°C, or stored at 4°C for 9 days. ShE-CDCP1 concentration in samples 
was measured after each cycle by ELISA in triplicate wells. 
 
2.6 ELISA analysis of ShE-CDCP1 in human serum samples 
 
Human serum samples were collected from individuals attending the Princess Alexandra 
Hospital colorectal unit, with written informed consent under a protocol approved by the 
institutional human research ethics committee (approval 2006/178). In total 32 samples (4 
benign, 28 colorectal cancer) were analysed. Diagnosis was established by pathologist 
assessment of colon tissue specimens that were collected at the same time as blood. Clinical data 
collected was age and gender for all cases and, for colorectal cancers, stage and the concentration 
of the biomarker carcinoembryonic antigen (CEA) which is employed clinically to monitor for 
recurrent colorectal cancer [33]. The concentration of ShE-CDCP1 in these samples was 
assessed using the optimized and validated ELISA. Samples were diluted 1:5 in dilution buffer, 
applied to duplicate wells (100 μl/well) and assays were performed three times.   
 
3. Results 
 
3.1 Specificity of anti-CDCP1 antibodies AF2666 and 10D7, and generation of the reference 
standard 
 
As summarized in Figure 1A, the ECD of CDCP1 spans residue 30 to 666, and is shed from the 
surface of cultured cell lines by cleavage at R368 and K369, generating fragments of about 65 
kDa, designated ShE-CDCP1, that are stable in conditioned media [20] and present in urine of 
prostate cancer patients [21]. CDCP1 cleavage is apparent in a wide range of cancer cell lines 
including those derived from colorectal tumors [3]. Our goal was to develop an ELISA that can 
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determine the concentration of ShE-CDCP1 present in human specimens. For this purpose we 
required a purified form of CDCP1 that is suitable for use as a reference standard, as well as 
antibodies that are capable of specifically detecting ShE-CDCP1 from complex protein mixtures. 
 
To generate a reference standard, we purified rCDCP1-ECD from the conditioned media of 
stably expressing HEK293 cells using metal affinity chromatography. As shown in Figure 1B, a 
silver stained gel of three independent purifications indicated that rCDCP1-ECD purity was 
>98%. Using known concentrations of BSA, the concentration of the three batches of reference 
standard was determined as 122, 103 and 65 µg/ml. 
 
For capture of ShE-CDCP1 we employed in the ELISA a previously published mouse 
monoclonal antibody, 10D7 [17], and for detection a commercial goat polyclonal antibody, 
AF2666, previously used to detect ShE-CDCP1 in conditioned media of cell lines [20]. We 
examined the specificity of these antibodies by Western blot analysis of conditioned media from 
HEK293 cells stably expressing ShE-CDCP1368, ShE-CDCP1369 or CDCP1-ECD. As shown in 
Figure 1C, from the complex mixtures of human proteins present in the respective conditioned 
media, both antibodies specifically detected only ShE-CDCP1368, ShE-CDCP1369 and CDCP1-
ECD. For CDCDP1-ECD there was evidence of its cleavage in conditioned media as indicated 
by the presence of bands detected by both 10D7 and AF2666 at ~65 kDa likely due to the 
activity of an endogenous protease (Fig 1C). To further assess antibody specificity we also 
performed an immunopurification, using 10D7, from the conditioned media of HEK293-ShE-
CDCP1369 cells. As show in Figure 1D, AF2666 Western blot analysis of the 10D7 
immunopurified fraction detected only ShE-CDCP1369. These analyses confirm the specificity of 
10D7 and AF2666 for ShE-CDCP1. The data also indicate that the 10D7/AF2666 antibody pair 
is suitable for use in an ELISA to quantify the concentration of ShE-CDCP1 present in biological 
samples. In addition, the data demonstrate that the epitopes recognized by the capture and 
detection antibodies are present between residue 30 and 368 of CDCP1. 
 
3.2 Optimization and validation of ELISA  
 
3.2.1 Optimization of the concentration of capture and detection antibodies used in the ELISA 
 
The concentration of the capture antibody (10D7) and the biotinylated detection antibody 
AF2666 used in the ELISA was optimized using a checkerboard titration approach. As shown in 
Table 1, high signals were achieved at all concentrations of 10D7 when AF2666 was applied at ≥ 
0.2 µg/ml/well, and near maximum OD was achieved when 10D7 concentration was 4 
µg/ml/well. As the highest signal to noise ratio, 12.7, was achieved at a 10D7 concentration of 4 
µg/ml/well and AF2666 at 0.2 µg/ml/well, these optimised values were used in subsequent 
assays. 
 
3.2.2 Determination of the MRD to be used for samples 
 
As the sample matrix (in this case serum) can interfere with detection of the analyte, it is 
necessary to determine the MRD of the sample that provides the most accurate measurement of 
analyte concentration [28, 34]. This was performed using a test for linearity in which serum 
pooled from five colorectal cancer patients was spiked with the reference standard to a 
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concentration of 80 ng/ml. The ELISA was performed on the neat sample and on a dilution series 
from 1:1 to 1:23 (spiked sample:dilution buffer). The concentration obtained at each dilution is 
shown at Table 2. The MRD, which is the lowest dilution at which the measured concentration is 
within 90-110% of the previous concentration, was observed at a dilution of 1:5 (Table 2). This 
was selected as the MRD and used as the sample dilution in subsequent ELISAs. 
 
3.2.3 The reference standard curve is suitable for determining ShE-CDCP1 concentration in serum 
 
To examine whether the reference standard curve is suitable for determining ShE-CDCP1 
concentration in serum, we performed tests for parallelism. These examined the correlation 
between ELISA measurements determined for the reference standard diluted in dilution buffer or 
serum. As shown in Figure 2, data were overlaid as curves of best fit, or log10 transformed then 
overlaid as lines of best fit. In both cases the data were almost completely coincident. Regression 
analysis demonstrated r2 > 0.97 for the lines of best fit, and Tukey’s HSD analysis showed there 
was no significant difference between these lines. These analyses indicate that the reference 
standard curve is suitable for determining ShE-CDCP1 concentration in serum. 
 
3.2.4 Working range of the ELISA - determination of LOD, LLOQ and ULOQ 
 
The LLOQ and ULOQ, which delineate the working range of the assay, were determined using 
the reference standard curve as described previously [26, 27]. The LLOQ is the concentration 
from the reference standard that is 10 standard deviations from the mean of 10 blank wells, while 
the ULOQ is the value derived from the highest absorbance from the reference standard curve 
for which the coefficient of variation (CV) is less than 10%. In terms of accuracy, mean 
concentrations should be within 15% of the nominal values for the QC samples, except for the 
LLOQ which should be within 20% of the nominal value [31]. Using these approaches LLOQ 
and ULOQ were determined as 0.68 ng/ml and 26.5 ng/ml, respectively. The LOD of the assay, 
the lowest concentration that can be differentiated from a blank (ie. the S/N ratio is ≥ 3), is 0.25 
ng/ml, and was also determined from the reference standard curve as described previously [27] 
by performing the ELISA on 10 blank wells containing only dilution buffer. 
 
3.2.5 Precision and accuracy of the anti-ShE-CDCP1 ELISA 
 
The precision and accuracy of the ELISA was assessed using QC samples of colorectal cancer 
patient serum spiked with the reference standard to represent cases with low, medium and high 
concentrations of analyte. As shown in Table 3, the ELISA displayed both high intra-assay 
(repeatability) and high inter-assay (reproducibility) precision with all CVs ≤ 7%. The ELISA 
also displayed high accuracy. This was examined by assessing the recovery rate of the ELISA, 
which is the actual measured concentration of analyte divided by the total of spiked reference 
standard and endogenous ShE-CDCP1 in the sample. As shown in Table 4, the recovery rate 
ranged from 95.8% for low, 98.3% for medium, and 99.6% for high concentration QC samples.  
 
3.3 ShE-CDCP1 is stable in serum 
 
The stability of ShE-CDCP1 in serum was tested by subjecting QC samples to six cycles of 
freezing and thawing from -80°C, and prolonged storage at -20°C and 4°C. As shown in Table 5, 
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we observed that for the three tested conditions, the measured concentrations were within 4.3% 
of actual concentrations, indicating that ShE-CDCP1 is stable in serum.  
 
3.4 The developed ELISA detects ShE-CDCP1 in human serum  
 
To evaluate the developed ELISA, we used it to measure ShE-CDCP1 concentration in a small 
number of human serum specimens including samples from four individuals with benign 
conditions, and 28 diagnosed with colorectal cancer (Fig 3A). The colorectal cancer samples 
were from cases with stage I (invasion into but not through the bowel wall), stage II (invasion 
through the bowel wall), stage III (metastasis to regional lymph nodes) and stage IV (distant 
metastasis) disease. All samples were tested in duplicate with three biological replicates. As 
shown in Figure 3B, ShE-CDCP1 concentration was ~50% higher in serum of colorectal cancer 
patients compared with benign cases. In addition, while there was no statistically significant 
difference between ShE-CDCP1 levels in benign cases and patients with localized colorectal 
cancer (stage I), patients who displayed invasive disease beyond the bowel wall (stage II-IV) had 
significantly higher levels when compared with benign cases and stage I colorectal cancer cases 
(Fig 3C). In these cases the current blood biomarker for colorectal cancer recurrence, CEA [35], 
was markedly elevated only in stage IV cases compared with the other stages, and this elevation 
was statistically significant (p<0.05; Fig 3A).  
4. Discussion 
 
Here we report the development of the first ELISA to measure the concentration of ShE-CDCP1 
in human serum. The assay employs a mouse monoclonal antibody as the capture reagent and a 
goat polyclonal antibody as the detection reagent. Our data demonstrate that both of these 
antibodies recognize an epitope that is present in the portion of CDCP1 that is shed from the 
surface of cells. This contrasts with anti-CDCP1 ELISAs that are currently available from 
commercial suppliers, which are designed to detect only the full-length protein and are thus not 
capable of detecting ShE-CDCP1.  
 
The developed anti-ShE-CDCP1 ELISA is sensitive and has high precision and accuracy. Its 
working range is from 0.68 to 26.5 ng/ml, with a LOD of 0.25 ng/ml. In addition, linearity of 
dilution was tested with the result that a 1:5 MRD was applied to all specimens, reducing 
interference from other components of the matrix, while keeping the samples as concentrated as 
possible. Parallelism between standard reference curves and calibration curves was observed, 
which demonstrated that the ELISA could be used to determine ShE-CDCP1 concentrations in 
patient samples. 
 
The developed ELISA was used to measure the concentration of ShE-CDCP1 in pre-treatment 
serum of colorectal cancer patients. Our data indicate that ShE-CDCP1 levels are higher in 
serum of these patients compared with individuals with benign tumors. In addition, when 
malignant cases were stratified by stage, the level of ShE-CDCP1 was significantly higher in 
patients with stage II to IV tumors. In contrast, the current blood biomarker for recurrence of 
colorectal cancer, CEA, was elevated only in stage IV cases [33]. The apparent correlation of 
elevated ShE-CDCP1 with stage II to IV disease may result from the disruption of normal organ 
architecture that occurs during progression of colorectal cancer. Whereas malignant cells remain 
localised within the colon of stage I tumors, in higher stages these cells escape the confines of 
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the colonic mucosa including to the colonic serosa, nearby organs, lymph nodes and/or distant 
sites [35]. Thus, ShE-CDCP1 could be expected to be present at elevated levels in the 
vasculature of those patients with stage II and higher stage disease. While these data suggest that 
ShE-CDCP1 could be useful for diagnosis of stage II to IV colorectal cancers, analysis of pre-
treatment bloods from larger patient cohorts is necessary to accurately assess this possibility. 
Currently there is no blood biomarker for colorectal cancer; the biomarker CEA is employed 
clinically to monitor for recurrent colorectal cancer [33]. Whether ShE-CDCP1 serum levels are 
more specific and sensitive than CEA concentration at detecting recurrent colorectal cancer 
requires analysis of post-treatment samples from large patient cohorts.  
 
5. Conclusion 
 
This report describes the development of a novel sandwich ELISA to quantify the concentration 
of ShE-CDCP1 in patient serum. We conclude that the assay is precise and reproducible, and that 
serum samples with a ShE-CDCP1 level above the upper LOQ can be diluted for analysis and 
measured accurately. We have shown for the first time that the level of ShE-CDCP1 is 
significantly higher in serum of colorectal cancer patients compared with the serum of 
individuals with benign conditions, and that elevated levels may be indicative of cancer that has 
spread beyond the colonic mucosa. The use of anti-ShE-CDCP1 ELISAs may potentially be 
extended to other malignancies as CDCP1 is cleaved in a wide range of cancer cell lines [3, 20], 
fragments of CDCP1 are present in the urine of prostate cancer patients at high risk of poor 
survival [21], and CDCP1 cleavage is necessary for triple negative breast cancer migration [23] 
and for vascular metastasis in animal models [15, 16]. 
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Figure Legends 
 
Fig. 1. CDCP1 structure and reagents. (A) Structural features of CDCP1 including its orientation 
at the cell surface and cleavage mediated by serine proteases (scissors). Cleavage occurs at 
adjacent sites (R368 and K369; arrow) which releases 65 kDa ShE-CDCP1 fragments from the 
cell surface. (B) Silver stained SDS denatured gel of BSA standards and three independent 
purifications (B1, B2, B3) of rCDCP1-ECD. (C) Anti-CDCP1 Western blot analysis of 
conditioned media (10 µl) from HEK293 cells stably expressing ShE-CDCP1368, ShE-CDCP1369 
or CDCP1-ECD. Membranes were probed with AF2666 (0.8 µg/ml) and 10D7 (5.0 µg/ml). (D) 
Anti-CDCP1 Western blot analysis (antibody AF2666; 0.8 µg/ml) of proteins 
immunoprecipitated from the conditioned media (300 µl) of HEK293-ShE-CDCP1369 cells using 
antibody 10D7 or isotype matched IgG (4 µg). 
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Fig. 2. ELISA validation assessing parallelism between the reference standard curve and the 
calibrator curve. (A) Plot of ELISA OD versus analyte concentration, generated for the reference 
standard (100, 61, 30.5, 15.25, 7.625, 3.8125, 1.91, 0.95, 0.476, 0.238, 0.119 ng/ml) diluted in 
either dilution buffer (Standard) or buffer consisting of equal volumes of serum from five 
colorectal cancer patients that had been diluted 1:5 in dilution buffer (Serum). (B) Linear plot of 
the data from panel A transformed using the operator log10. 
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Fig. 3. ELISA for ShE-CDCP1 in human serum. (A) Summary of the colorectal cancer cases 
separated into benign and malignant cases including number and gender of cases, and, for 
malignant cases, CEA concentration. (B) Graphical representation of ShE-CDCP1 concentration 
present in benign cases (n = 4) versus colorectal cancer cases (n = 28). (C) Graphical 
representation of ShE-CDCP1 concentration present in stage I (n = 8), stage II (n = 7), stage III 
(n = 4) and stage IV (n = 9) colorectal cancer cases. (D) Graphical representation of CEA 
concentration present in the same colorectal cancer cases. Values in (B) and (C) are mean ± 
SEM, aggregated from data from three assays that each included duplicate wells. Statistical 
significance was assessed using a one way ANOVA and Welch’s t-test to adjust for unequal 
sample sizes.  
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Table 1 Checkerboard titration to determine the optimal concentration of capture (10D7) and 
detection (biotinylated AF2666) antibodies for use in the ELISA. rCDCP1-ECD at 10 ng/ml/well 
in dilution buffer was used as the analyte. 
 
 AF2666 10D7 (µg/ml) 
Row (µg/ml) 11 10 9 8 7 6 5 4 3 2 1 0 
1 0.8 1.95 2.05 1.96 2.02 2.02 1.95 2.05 1.56 1.98 1.81 1.59 0.20 
2 0.4 1.72 1.75 1.70 1.74 1.83 1.79 1.72 1.76 1.76 1.64 1.82 0.12 
3 0.2 1.25 1.31 1.42 1.40 1.40 1.37 1.39 1.45 1.45 1.36 1.21 0.11 
4 0.1 0.90 0.98 1.01 0.98 0.95 0.99 0.97 1.00 0.99 0.97 0.79 0.10 
5 0.05 0.60 0.58 0.57 0.62 0.61 0.64 0.62 0.63 0.64 0.63 0.51 0.08 
6 0.025 0.34 0.37 0.37 0.36 0.37 0.38 0.36 0.38 0.37 0.38 0.35 0.09 
7 0.0125 0.20 0.21 0.21 0.21 0.23 0.23 0.26 0.22 0.21 0.20 0.23 0.07 
8 0 0.06 0.08 0.08 0.09 0.05 0.11 0.06 0.06 0.06 0.06 0.08 0.08 
 
 
Table 2 MRD analysis. The sample dilution required to minimise the impact of the sample 
matrix on the accuracy of the ELISA was examined by measuring analyte concentration in 
pooled serum samples from five randomly selected colorectal cancer patients that had been 
spiked with reference standard. MRD was determined as the dilution which is within 90-110% of 
actual and the % change in concentrations from previous dilution is within 80-120%. 
 
Dilution ELISA Value 
(ng/ml) 
% of actual % change from 
previous dilution 
Undiluted 48.8 61.0 NA 
1:1 73.8 92.2 151.2 
1:3 65.9 79.4 89.3 
1:5 77.4 96.8 117.5 
1:7 75.3 94.1 97.3 
1:15 80.3 100.0 106.6 
1:23 85.2 106.5 106.1 
 
 
 
Table 3 Intra- (repeatability) and inter-assay (reproducibility) precision of the anti-ShE-CDCP1 
ELISA. 
 
 Nominal 
Concentration 
Intra-assay 
(n = 12) 
Inter-assay 
(n = 12) 
 (ng/ml) Value (ng/ml) CV (%) Value (ng/ml) CV (%) 
High 18.7 17.7 5.5 17.4 7.0 
Medium 9.1 9.36 2.9 9.36 2.9 
Low 1.5 1.44 3.6 1.58 5.1 
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Table 4 Accuracy of the anti-ShE-CDCP1 ELISA, assessed using a recovery test of randomly 
pooled colorectal patient serum samples spiked with recombinant CDCP1-ECD standard. 
 
 
 
 
 
 
 
 
 
 
Table 5 Stability of ShE-CDCP1. Concentration of ShE-CDCP1 (40 ng/ml) after the indicated 
periods of storage determined using the developed ELISA. 
 
 -80ºC freeze/thaw cycle 9 days 9 days 
 1 2 3 4 5 6 at 4ºC at -20ºC 
Concentration (ng/ml) 41.1 41.7 39.4 39.6 40.0 39.7 39.0 40.1 
Bias (%)  2.75 4.25 1.5 1.0 0 0.75 2.5 0.25 
 
 
 QC Sample 
 High Medium Low 
Spiked concentration (ng/ml) 16.86 4.55 1.06 
Mean of measured concentration 
(ng/ml) 
15.98 4.37 1.02 
SD of measured concentration 0.75 0.11 0.03 
Accuracy (% recovery) 94.8 96.0 96.2 
